ADAMTS13 and Schnyder corneal dystrophy: Notably, pharmacologic or genetic reduction of endothelial VWF, or administration of recombinant ADAMTS-13, attenuates vaso-occlusion, inflammation, hemolysis, and organ damage in multiple SCD mouse models, even when administered after an acute insult [[71], [72], [73], [74]].